Association between glucokinase regulatory protein (GCKR) and apolipoprotein A5 (APOA5) gene polymorphisms and triacylglycerol concentrations in fasting, postprandial, and fenofibrate-treated states

Am J Clin Nutr. 2009 Jan;89(1):391-9. doi: 10.3945/ajcn.2008.26363. Epub 2008 Dec 3.

Abstract

Background: Hypertriglyceridemia is a risk factor for cardiovascular disease. Variation in the apolipoprotein A5 (APOA5) and glucokinase regulatory protein (GCKR) genes has been associated with fasting plasma triacylglycerol.

Objective: We investigated the combined effects of the GCKR rs780094C-->T, APOA5 -1131T-->C, and APOA5 56C-->G single nucleotide polymorphisms (SNPs) on fasting triacylglycerol in several independent populations and the response to a high-fat meal and fenofibrate interventions.

Design: We used a cross-sectional design to investigate the association with fasting triacylglycerol in 8 populations from America, Asia, and Europe (n = 7,730 men and women) and 2 intervention studies in US whites (n = 1,061) to examine postprandial triacylglycerol after a high-fat meal and the response to fenofibrate. We defined 3 combined genotype groups: 1) protective (homozygous for the wild-type allele for all 3 SNPs); 2) intermediate (any mixed genotype not included in groups 1 and 3); and 3) risk (carriers of the variant alleles at both genes).

Results: Subjects within the risk group had significantly higher fasting triacylglycerol and a higher prevalence of hypertriglyceridemia than did subjects in the protective group across all populations. Moreover, subjects in the risk group had a greater postprandial triacylglycerol response to a high-fat meal and greater fenofibrate-induced reduction of fasting triacylglycerol than did the other groups, especially among persons with hypertriglyceridemia. Subjects with the intermediate genotype had intermediate values (P for trend <0.001).

Conclusions: SNPs in GCKR and APOA5 have an additive effect on both fasting and postprandial triacylglycerol and contribute to the interindividual variability in response to fenofibrate treatment.

Publication types

  • Multicenter Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adaptor Proteins, Signal Transducing / genetics*
  • Adult
  • Aged
  • Apolipoprotein A-V
  • Apolipoproteins A / genetics*
  • Cross-Sectional Studies
  • Dietary Fats / administration & dosage
  • Dietary Fats / metabolism
  • Fasting / blood
  • Female
  • Fenofibrate / therapeutic use
  • Gene Frequency
  • Genetic Predisposition to Disease
  • Genetic Variation
  • Genotype
  • Humans
  • Hypertriglyceridemia / blood
  • Hypertriglyceridemia / drug therapy
  • Hypertriglyceridemia / epidemiology
  • Hypertriglyceridemia / genetics*
  • Hypolipidemic Agents / therapeutic use*
  • Male
  • Middle Aged
  • Polymorphism, Single Nucleotide / genetics*
  • Postprandial Period
  • Risk Factors
  • Treatment Outcome
  • Triglycerides / blood*
  • Triglycerides / genetics
  • Young Adult

Substances

  • APOA5 protein, human
  • Adaptor Proteins, Signal Transducing
  • Apolipoprotein A-V
  • Apolipoproteins A
  • Dietary Fats
  • GCKR protein, human
  • Hypolipidemic Agents
  • Triglycerides
  • Fenofibrate